Key facts
- This page summarizes Michael Sinclair's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 25 Aug 2021, 16:38.
Michael Sinclair - 23 Aug 2021 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 23 Aug 2021
- Net transaction value
- -$1,606,674
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2021, 16:38:32 UTC
- Next SEC filing
- 06 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Sinclair
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Sinclair filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 25 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$1,606,674.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPNT
transaction
Common Stock, par value $0.001 per share
Options Exercise
- Transaction value
- $325,620
- Shares
- +65,124
- Change %
- +45%
- Price
- $5.00
- Shares after
- 209,194
- Date
- 23 Aug 2021
- Ownership
- Direct
OPNT
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $1,074,546
- Shares
- -65,124
- Change %
- -31%
- Price
- $16.50
- Shares after
- 144,070
- Date
- 23 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
OPNT
transaction
Common Stock, par value $0.001 per share
Options Exercise
- Transaction value
- $173,035
- Shares
- +34,607
- Change %
- +24%
- Price
- $5.00
- Shares after
- 178,677
- Date
- 24 Aug 2021
- Ownership
- Direct
OPNT
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $543,676
- Shares
- -34,607
- Change %
- -19%
- Price
- $15.71
- Shares after
- 144,070
- Date
- 24 Aug 2021
- Ownership
- Direct
- Footnotes
- F2
OPNT
transaction
Common Stock, par value $0.001 per share
Options Exercise
- Transaction value
- $251,345
- Shares
- +50,269
- Change %
- +35%
- Price
- $5.00
- Shares after
- 194,339
- Date
- 25 Aug 2021
- Ownership
- Direct
OPNT
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $738,452
- Shares
- -50,269
- Change %
- -26%
- Price
- $14.69
- Shares after
- 144,070
- Date
- 25 Aug 2021
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OPNT
transaction
Derivative
Options
Options Exercise
- Transaction value
- $0
- Shares
- -65,124
- Change %
- -43%
- Price
- $0.000000
- Shares after
- 84,876
- Date
- 23 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 65,124
- Exercise price
- $5.00
- Footnotes
- F4
OPNT
transaction
Derivative
Options
Options Exercise
- Transaction value
- $0
- Shares
- -34,607
- Change %
- -41%
- Price
- $0.000000
- Shares after
- 50,269
- Date
- 24 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 34,607
- Exercise price
- $5.00
- Footnotes
- F4
OPNT
transaction
Derivative
Options
Options Exercise
- Transaction value
- $0
- Shares
- -50,269
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 50,269
- Exercise price
- $5.00
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F4
These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.